Jaschinski U
Klinik für Anästhesiologie und Operative Intensivtherapie, Klinikum Augsburg, Stenglinstr. 2, 86156, Augsburg, Deutschland.
Anaesthesist. 2016 Dec;65(12):951-970. doi: 10.1007/s00101-016-0242-8.
Aneurysmal subarachnoid hemorrhage (SAH) is a devastating disease and nearly one third of patients die in the acute phase. Due to the bleeding event, a hyperactive sympathetic nervous system and an uncontrolled inflammatory response have a profound local and systemic impact on other organ functions. Neuroendocrinological disorders and cardiopulmonary morbidity are dominant. Despite a decrease in hospital mortality for high volume centers, a high proportion of survivors suffer from neurological deficits. Knowledge of the pathophysiology of vasospasms in the later stages of the disease has increased. Anti-inflammatory treatment does not improve the outcome. Nimodipine prophylaxis in the first 96 h after SAH seems to be the only intervention which has been proven to be advantageous in studies; however, nearly every second survivor of SAH suffers from some neurological deficits and more than one third of survivors report depressive episodes or symptoms of posttraumatic stress disorder.
动脉瘤性蛛网膜下腔出血(SAH)是一种毁灭性疾病,近三分之一的患者在急性期死亡。由于出血事件,过度活跃的交感神经系统和失控的炎症反应会对其他器官功能产生深远的局部和全身影响。神经内分泌紊乱和心肺疾病较为突出。尽管大容量中心的医院死亡率有所下降,但仍有很大比例的幸存者存在神经功能缺损。对疾病后期血管痉挛病理生理学的认识有所增加。抗炎治疗并不能改善预后。SAH后96小时内使用尼莫地平预防似乎是唯一在研究中被证明有益的干预措施;然而,几乎每两名SAH幸存者中就有一人存在某种神经功能缺损,超过三分之一的幸存者报告有抑郁发作或创伤后应激障碍症状。